Melanotan I vs Melanotan II

Overview

Melanotan I (afamelanotide) and Melanotan II are both synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide that regulates melanin production in the skin. Despite sharing a similar name and common origin, the two peptides differ substantially in their receptor selectivity, side effect profiles, and the scope of physiological effects they produce.

Both compounds were originally developed at the University of Arizona in the 1980s and 1990s. Melanotan I followed a more conventional pharmaceutical development pathway and eventually received limited regulatory approval in Europe (as Scenesse® for erythropoietic protoporphyria). Melanotan II remained an unregulated research compound but gained widespread attention due to its broader range of biological effects.

Quick Comparison Table

Mechanism of Action: Selectivity Is the Key Difference

Melanotan I is a relatively selective agonist of the melanocortin 1 receptor (MC1R). This receptor sits on melanocytes — the cells in the skin that produce melanin. When MT-I binds MC1R, it triggers the cAMP signalling cascade that increases eumelanin synthesis, resulting in darker pigmentation. Because MT-I primarily targets MC1R, its effects are largely confined to skin pigmentation with fewer off-target actions.

Melanotan II is a non-selective melanocortin agonist. It binds strongly to MC1R (pigmentation), MC3R (energy homeostasis and cardiovascular regulation), MC4R (sexual arousal, appetite, and energy balance), and MC5R (exocrine gland function). This broad receptor activation explains why MT-II produces a wider array of effects: tanning, increased libido, reduced appetite, and various metabolic changes. The MC4R activation is responsible for the sexual arousal effect that led to the development of PT-141 (bremelanotide), a derivative of Melanotan II.

Pigmentation Research: Both Effective, Different Profiles

Both peptides effectively increase melanin production, but their pigmentation profiles differ in subtle ways.

Melanotan I produces a more gradual, even tan that develops over weeks. Because it is selective for MC1R, the tanning effect is considered more predictable and uniform. Research with afamelanotide implants showed sustained increases in melanin density over 60 days. The pigmentation is predominantly eumelanin (the darker, more photoprotective form), which may explain its utility in photoprotection research for conditions like erythropoietic protoporphyria.

Melanotan II tends to produce a faster, more dramatic tanning effect — often noticeable within days. However, the pigmentation can be more uneven, with darkening of existing moles and freckling reported more frequently. The rapid onset is attributed to MT-II's stronger binding affinity and longer half-life.

Beyond Tanning: Where MT-II Diverges

The most significant practical difference between MT-I and MT-II is what MT-II does beyond skin pigmentation.

Sexual Function (MC4R Activation)

Melanotan II's activation of MC4R receptors in the hypothalamus produces notable pro-sexual effects. Research documented increased sexual arousal in both male and female subjects. This effect was significant enough that a modified version — PT-141 (bremelanotide) — was developed specifically as a sexual dysfunction treatment and eventually received FDA approval for hypoactive sexual desire disorder in premenopausal women.

Melanotan I does not produce these sexual effects at standard dosages because it has minimal MC4R activity.

Appetite Suppression

MC4R is heavily involved in appetite regulation. MT-II consistently demonstrates appetite-suppressing effects in both animal and human research. MT-I does not meaningfully affect appetite, again due to its MC1R selectivity.

Safety Comparison

Melanotan I has the strongest safety profile of the two, supported by clinical trial data from the Scenesse® development programme. Common side effects include nausea (usually transient), facial flushing, fatigue, and headache. Serious adverse events in clinical trials were rare. The primary long-term concern is the theoretical risk of melanoma promotion through chronic melanocyte stimulation, though clinical data has not confirmed this risk.

Melanotan II carries higher risk due to its non-selective receptor activation. Beyond the nausea and flushing common to both, MT-II can cause spontaneous erections, changes in mole appearance, increased blood pressure, and facial flushing. The broader melanocortin activation means more potential for unpredictable effects. There have been case reports of new or changing nevi (moles) in MT-II users, which raises dermatological monitoring concerns. Both peptides must be properly reconstituted before use and stored according to proper handling guidelines.

Canadian Context

Neither peptide is approved by Health Canada for therapeutic use — see our Canadian legality guide. Both are available through Canadian research chemical suppliers as “not for human consumption” products. Melanotan II in particular has been the subject of Health Canada advisories warning consumers against self-injection of unregulated tanning products. Always verify purity through Certificates of Analysis.

It's worth noting that Scenesse® (afamelanotide) has been approved by the European Medicines Agency (EMA) and the Australian TGA for erythropoietic protoporphyria. Patients in Canada seeking this treatment would need to explore special access programs or travel abroad.

Bottom Line for Researchers

• Pure pigmentation research? Melanotan I offers a more selective, predictable model with fewer confounding off-target effects.
• Sexual function or appetite research? Melanotan II (or its derivative PT-141) is the relevant compound due to MC4R activation.
• Photoprotection studies? Melanotan I has clinical data supporting eumelanin production and UV protection.
• Broad melanocortin system research? Melanotan II's non-selective binding makes it useful for studying multiple melanocortin pathways simultaneously.